CSL Behring joins NEWDIGS FoCUS Project

Eric NormanFoCUS, News

Collaboration to improve accessibility and sustainability of new cell and gene therapiesThursday, May 27, 2021 Global biotherapeutic leader CSL Behring has joined the Massachusetts Institute of Technology Center for Biomedical Innovation’s New … Read More

FoCUS Monthly Recap: March 2021

Eric NormanFoCUS, News

NEW RESEARCH Payer perspectives on outcomes tracking for value-based payment arrangements (VBPs) With the new CMS rule changing Medicaid Best Price reporting to encourage VBPs, many options are available for … Read More

Payer perspectives on outcomes tracking for value-based payment arrangements (VBPs)

Eric NormanFoCUS, Research Briefs

Share the researchWith the new CMS rule changing Medicaid Best Price reporting to encourage VBPs, many options are available for which healthcare system players will collect, protect and adjudicate the … Read More

The resource navigation challenges for patients and caregivers

Eric NormanFoCUS, Research Briefs

Share the researchWhile the problem of finding system-wide, implementable precision financing models for curative and durable therapies involves all stakeholders, patients and caregivers are directly affected by many different elements … Read More

FoCUS Monthly Recap: January 2021

Eric NormanFoCUS, News

RESEARCH BRIEF Resource navigation challenges for patients and caregivers While the problem of finding system-wide, implementable precision financing models for curative and durable therapies involves all stakeholders, patients and caregivers … Read More

FoCUS Monthly Recap: December 2020

Eric NormanFoCUS, News

IN THE MEDIAMark Trusheim coauthored the article “Market access of gene therapies across Europe, USA, and Canada: challenges, trends, and solutions” published in Science Direct: Drug Discovery Today, November 24, 2020. This review … Read More

FoCUS Monthly Recap: October 2020

Eric NormanFoCUS, News

WHITE PAPER Warranty Model: A potential precision financing solution for durable cell and gene therapies Durable cell and gene therapies are poised for rapid growth—posing transformative benefits for patients and … Read More

Warranty Model: A potential precision financing solution for durable cell and gene therapies

Eric NormanFoCUS, Whitepapers

Durable cell and gene therapies are poised for rapid growth – potentially providing transformative benefits for patients and exacerbating financial challenges for payers, providers, patients, and therapeutic developers. With five … Read More